Therapies Archives - Oncology Central Oncology Central

Must read

13 Feb 2019 Lung
Defining aggressive or early progressing non-oncogene-addicted non-small cell lung cancer: a separate disease entity?

12 Feb 2019 Brain and neurologic
Pembrolizumab could effectively treat recurrent glioblastoma, study suggests
6 Dec 2018 News
Palbociclib halts tumor growth in early breast cancer patients
19 Nov 2018
Dual-action virus targets both cancer cells and associated fibroblasts
14 Nov 2018 Clinical trials
Promising Phase I trial for anti-HER2 antibody
3 Nov 2018
NCRI 2018: Prostate cancer patients may prioritize the avoidance of side-effects over survival probability
8 Oct 2018 Breast
What are the top 5 breast cancer advancements of 2018?

Must watch

Stay up to date

Upcoming event

Gastrointestinal Cancers Symposium

January 17, 2019 – January 19, 2019

CA, USA

View all

Upcoming event

International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

February 9, 2019 – February 11, 2019

Kyoto, Japan

View all

Tweets

Oncology Central @OncologyCentral·

Discover a patients perspective on tumor mutation burden as a possible pathway for improvements in immuno-oncology. #OCtmb. Click on the image below for the full perspective: https://t.co/sywtJpAqz0

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Defining aggressive or early progressing non-oncogene-addicted non-small cell lung cancer: a separate disease entity?

Pembrolizumab could effectively treat recurrent glioblastoma, study suggests

Palbociclib halts tumor growth in early breast cancer patients

Dual-action virus targets both cancer cells and associated fibroblasts

Promising Phase I trial for anti-HER2 antibody

NCRI 2018: Prostate cancer patients may prioritize the avoidance of side-effects over survival probability

What are the top 5 breast cancer advancements of 2018?

A dog’s 3D printed implant shows potential for cancer surgeries

Zika vaccine yields promising results for treating glioblastoma

New tool could predict how cancer will resist drugs before they are given to patients

Capturing Cancer: Oncology Central Photography Competition

Vistusertib with paclitaxel shows promise for ovarian and lung cancer in early trial

Comprehensive CAR T-cell therapy pediatric guidelines developed

ASCO18: Day 3 update

ASCO18: Abiraterone for advanced prostate cancer may be more effective for black men than white men

Cause of resistance to olaparib and other PARP inhibitors identified

Advancing treatment options for medullary thyroid cancer: an interview with Jonathan Wadsley

Characteristics and treatment patterns among US patients with hairy cell leukemia

Accelerating clinical trials for stem cell transplantation

Non-small-cell lung cancer: the facts

PARP-inhibitor olaparib shows promise for glioblastoma

Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2- metastatic breast cancer

What are the treatment options for lymphoma? Chris Lewis’s story (Episode 2)

Login

Therapies

Must read

Defining aggressive or early progressing non-oncogene-addicted non-small cell lung cancer: a separate disease entity?

Pembrolizumab could effectively treat recurrent glioblastoma, study suggests

Palbociclib halts tumor growth in early breast cancer patients

Dual-action virus targets both cancer cells and associated fibroblasts

Promising Phase I trial for anti-HER2 antibody

NCRI 2018: Prostate cancer patients may prioritize the avoidance of side-effects over survival probability

What are the top 5 breast cancer advancements of 2018?

Must watch

A dog’s 3D printed implant shows potential for cancer surgeries

Zika vaccine yields promising results for treating glioblastoma

New tool could predict how cancer will resist drugs before they are given to patients

Capturing Cancer: Oncology Central Photography Competition

Vistusertib with paclitaxel shows promise for ovarian and lung cancer in early trial

Comprehensive CAR T-cell therapy pediatric guidelines developed

ASCO18: Day 3 update

ASCO18: Abiraterone for advanced prostate cancer may be more effective for black men than white men

Cause of resistance to olaparib and other PARP inhibitors identified

Advancing treatment options for medullary thyroid cancer: an interview with Jonathan Wadsley

Characteristics and treatment patterns among US patients with hairy cell leukemia

Accelerating clinical trials for stem cell transplantation

Non-small-cell lung cancer: the facts

PARP-inhibitor olaparib shows promise for glioblastoma

Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2- metastatic breast cancer

What are the treatment options for lymphoma? Chris Lewis’s story (Episode 2)

Stay up to date

Oncology Central Newsletter